Trudell Medical is expanding into respiratory diagnostics with an agreement to acquire Vyaire Medical RDx, which includes pulmonary function testing devices.
RT’s Three Key Takeaways:
- Acquisition Agreement Reached: Trudell Medical Ltd has announced its intent to acquire Vyaire Medical’s RDx business unit, pending court approval, which manufactures respiratory diagnostic products.
- Portfolio Expansion: The acquisition will allow Trudell Medical to expand its offerings by incorporating respiratory diagnostics into its existing range of lung health and aerosol delivery devices, with RDx operations continuing in Germany and California.
- Service Continuation: The agreement ensures that RDx customers will continue to receive support and services, with Trudell Medical planning to operate RDx as a separate business unit under its ownership.
Trudell Medical Ltd has reached an agreement to purchase the RDx business unit of Vyaire Medical. RDx manufactures respiratory diagnostic products that are used in hospitals and private clinics worldwide.
The purchase is subject to court approval and is expected to close in eight to 12 weeks. The acquisition will expand Trudell Medical’s market position in aerosol drug delivery and lung health devices to include respiratory diagnostics.
Trudell Medical intends to operate RDx as a separate business unit and maintain operations in Germany and California.
The acquisition would ensure the continuation of service to RDx customers. Earlier this year, Vyaire Medical filed for Chapter 11 Protection and announced the company was focused on selling its business units to stable, well-capitalized buyers.
Established Partnership
Vyaire’s respiratory diagnostics and ventilation solutions are currently distributed by Trudell Healthcare Solutions within the Canadian healthcare system.
“We welcome the opportunity to add Vyaire RDx’s people, products, and passion to our Trudell Medical family. Respiratory diagnostics help to enhance and extend lives. This is in perfect alignment with our ‘patient first’ core value across the Trudell Medical Group. Every day, we’re focused on designing and manufacturing products and services that improve patients’ lives,” says George Baran, executive chair of Trudell Medical Ltd, in a release.
Will Throp, CEO of Vyaire RDx, adds in a release, “Since establishing the market 70 years ago under Eric Jaeger’s leadership, Vyaire RDx has been a global leader in the pulmonary function testing space. As part of this legacy, Trudell have been an outstanding distribution partner for Vyaire RDx in Canada. This well-established relationship serves as a firm foundation for Vyaire RDx to become part of the Trudell family, which has clearly aligned values and shared business objectives built on placing the customer and our employees at the heart of all we do.”
Photo caption: Vyaire’s Vyntus ONE Pulmonary Function System is part of the company’s respiratory diagnostics offerings.
File photo
